Exelixis rises after lifting 2025 revenue forecast

Shares of cancer drugmaker Exelixis EXEL.O rise 5.6% to $39 premarket

Co late on Tuesday raised 2025 rev. forecast to between $2.25 billion and $2.35 billion, compared with prior view of between $2.15 billion and $2.25 billion

Co posted Q1 total rev. of $555.4 million, beating analysts' estimate of $498.2 million - data compiled by LSEG

Co posted Q1 adj. profit of 62 cents per share vs estimates of 36 cents per share on sales of its cancer drug, Cabometyx

As of last close, stock up 11% YTD